Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CNSX:ATT NASDAQ:PCT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATTAbattis BioceuticalsC$0.00C$0.05▼C$0.74N/AN/A1.42 million shsN/APCTPureCycle Technologies$12.59+1.6%$6.75$4.93▼$17.37$2.24B2.314.58 million shs6.69 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATTAbattis Bioceuticals0.00%0.00%0.00%0.00%0.00%PCTPureCycle Technologies+1.61%+32.11%+88.19%+44.88%+53.54%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATTAbattis BioceuticalsC$0.00C$0.05▼C$0.74N/AN/A1.42 million shsN/APCTPureCycle Technologies$12.59+1.6%$6.75$4.93▼$17.37$2.24B2.314.58 million shs6.69 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATTAbattis Bioceuticals0.00%0.00%0.00%0.00%0.00%PCTPureCycle Technologies+1.61%+32.11%+88.19%+44.88%+53.54%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATTAbattis Bioceuticals 0.00N/AN/AN/APCTPureCycle Technologies 2.50Moderate Buy$12.00-4.69% DownsideCurrent Analyst Ratings BreakdownLatest ATT, SDR, PCT, and MNG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026PCTPureCycle Technologies TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$7.00 ➝ $6.002/27/2026PCTPureCycle Technologies Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$16.00 ➝ $14.00(Data available from 5/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATTAbattis BioceuticalsN/AN/AN/AN/AN/AN/APCTPureCycle Technologies$8.35M272.70N/AN/A$0.04 per share314.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATTAbattis BioceuticalsN/AN/AN/AN/AN/AN/AN/AN/AN/APCTPureCycle Technologies-$182.57M-$1.47N/AN/AN/A-2,062.36%-393.01%-22.56%N/ALatest ATT, SDR, PCT, and MNG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026PCTPureCycle Technologies-$0.26-$0.21+$0.05-$0.21$3.83 million$4.13 million2/26/2026Q4 2025PCTPureCycle Technologies-$0.25-$0.42-$0.17-$0.14$6.37 million$2.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATTAbattis BioceuticalsN/AN/AN/AN/AN/APCTPureCycle TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATTAbattis BioceuticalsN/AN/AN/APCTPureCycle Technologies47.591.711.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATTAbattis BioceuticalsN/APCTPureCycle Technologies63.01%Insider OwnershipCompanyInsider OwnershipATTAbattis BioceuticalsN/APCTPureCycle Technologies18.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATTAbattis BioceuticalsN/AN/AN/ANot OptionablePCTPureCycle Technologies120180.86 million146.86 millionNot OptionableATT, SDR, PCT, and MNG HeadlinesRecent News About These CompaniesPureCycle Technologies: Scale-Up Risk Still Outweighs The Growth CaseMay 15 at 12:30 AM | seekingalpha.comPureCycle Technologies: Until Ironton Scales, I'm WaitingMay 15 at 10:01 AM | seekingalpha.comPureCycle Technologies IncMay 14 at 11:51 PM | edition.cnn.comWhy PureCycle Technologies, Inc.’s (PCT) Stock Is Up 14.61%May 14 at 11:51 PM | aaii.comAPureCycle (PCT) Hits New Regulatory Milestone, Surges 21.5%May 14 at 11:51 PM | finance.yahoo.comPureFive® Resin Officially Qualifies as "Recycled Content" Following NJDEP ReviewMay 14 at 8:00 AM | globenewswire.comDrive Wealth Management LLC Purchases New Position in PureCycle Technologies, Inc. $PCTMay 11, 2026 | marketbeat.comFY2026 EPS Estimates for PCT Boosted by Northland SecuritiesMay 11, 2026 | marketbeat.comPureCycle Technologies, Inc. (NASDAQ:PCT) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesMay 10, 2026 | marketbeat.comTD Cowen Has Lowered Expectations for PureCycle Technologies (NASDAQ:PCT) Stock PriceMay 10, 2026 | americanbankingnews.comPureCycle Technologies (NASDAQ:PCT) Stock Rating Lowered by Wall Street ZenMay 10, 2026 | americanbankingnews.comPureCycle Technologies (NASDAQ:PCT) Downgraded by Wall Street Zen to Strong SellMay 10, 2026 | marketbeat.comPurecycle Technologies Signals Momentum Amid Ongoing LossesMay 9, 2026 | theglobeandmail.comPureCycle Reports Record Production and Extends Warrant ExpirationMay 8, 2026 | theglobeandmail.comAnalysts Offer Insights on Industrial Goods Companies: PureCycle Technologies (PCT), Emerson Electric Company (EMR) and GXO Logistics (GXO)May 8, 2026 | theglobeandmail.comStock Traders Buy Large Volume of Call Options on PureCycle Technologies (NASDAQ:PCT)May 8, 2026 | marketbeat.comTD Cowen Lowers PureCycle Technologies (NASDAQ:PCT) Price Target to $6.00May 8, 2026 | marketbeat.comPCT stock on track for its best day in over a year – and retail believes the real upside lies aheadMay 7, 2026 | msn.comPureCycle Technologies (NASDAQ:PCT) Shares Gap Up After Earnings BeatMay 7, 2026 | marketbeat.comPureCycle Technologies Q1 Earnings Call HighlightsMay 6, 2026 | marketbeat.comPureCycle (PCT) Q1 2026 Earnings TranscriptMay 6, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesApple’s Earnings Make $300 Look Like a Matter of When, Not IfBy Sam Quirke | May 1, 2026Why Lockheed Martin's Earnings Miss Could Be a Blessing in DisguiseBy Sam Quirke | May 4, 2026How the 3 Leading Quantum Firms Stack Up After Q1 EarningsBy Nathan Reiff | May 14, 2026Tesla’s Earnings Confirm the Shift to AI—But at What Cost?By Sam Quirke | April 23, 2026Big Bank Earnings Gave Financials a Lift, But Wall Street Is Still CautiousBy Jessica Mitacek | April 22, 2026ATT, SDR, PCT, and MNG Company DescriptionsAbattis Bioceuticals CNSX:ATTAbattis Bioceuticals Corp. is a specialty biotechnology company. The Company aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. It operates through the segment of producing, licensing and marketing ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The Company, through its subsidiaries, develops and commercializes natural health (nutraceutical) products, and conducts research and development to create plant-based (botanical) intellectual property and ingredients for the pharmaceutical and bioceutical markets, among others. It offers products and services, such as botanical blends and formulas; cannabidiol ingredients; functional foods and beverages, and analytical services. It is focused on creating botanical formulations, medical marijuana and specialized health products for pain caused by inflammation, and mental ailments.PureCycle Technologies NASDAQ:PCT$12.59 +0.20 (+1.61%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$12.46 -0.13 (-1.06%) As of 05/15/2026 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PureCycle Technologies, Inc. engages in the production of recycled polypropylene (PP). The company holds a license for restoring waste PP into ultra-pure recycled polypropylene resin that has multiple applications, including packaging and labeling for consumer products, piping, ropes, cabling, and plastic parts for various industries. Its recycling process separates color, odor, and other contaminants from plastic waste feedstock to transform it into virgin-like resin. The company was founded in 2015 and is headquartered in Orlando, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Peloton Stock Gives Back Gains After Upbeat Earnings Report MarketBeat Week in Review – 05/11 - 05/15 Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Alphabet's Googlebook Brings Gemini AI to PC Hardware Viking Sails to All-Time Highs—Fundamentals Signal More to Come YETI Rallies After Earnings Beat and Raised Outlook Aeluma's Post-Earnings Dip Creates a Buying Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
